EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL/RANK - from bone physiology to breast cancer



RANKL/RANK - from bone physiology to breast cancer



Cytokine & Growth Factor Reviews 25(2): 205-214



RANK and its ligand RANKL are key molecules in bone metabolism and are critically involved in pathologic bone disorders. Deregulation of the RANK/RANKL system is for example a main reason for the development of postmenopausal osteoporosis, which affects millions of women worldwide. Another essential function of RANK and RANKL is the development of a functional lactating mammary gland during pregnancy. Sex hormones, in particular progesterone, induce RANKL expression resulting in proliferation of mammary epithelial cells. Moreover, RANK and RANKL have been shown to regulate mammary epithelial stem cells. RANK and RANKL were also identified as critical mechanism in the development of hormone-induced breast cancer and metastatic spread to bone. In this review, we will focus on the various RANK/RANKL functions ranging from bone physiology, immune regulation, and initiation of breast cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333211

Download citation: RISBibTeXText

PMID: 24486161

DOI: 10.1016/j.cytogfr.2014.01.002



Related references

RANKL/RANK: from bone loss to the prevention of breast cancer. Open Biology 6(11): -, 2016

The many roles of RANKL-RANK signaling in bone, breast and cancer. Ibms Bonekey 8(5): 237-256, 2011

Involvement of RANKL/RANK pathway in bone metastasis in breast cancer. Clinical Calcium 21(8): 1159-1166, 2011

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. Journal of Experimental & Clinical Cancer Research 38(1): 12-12, 2019

Expression of RANK and RANKL is altered in invasive carcinoma and bone metastasis of breast cancer. Journal of Bone & Mineral Research 17(Suppl 1): S411, September, 2002

Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients. Biomed Research International 2014: 842452-842452, 2014

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clinical Breast Cancer 11(6): 369-375, 2012

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Research 33(1): 199-206, 2013

Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 31(5): 684-689, 2013

RANK/RANKL: regulators of immune responses and bone physiology. Annals of the New York Academy of Sciences 1143: 123-150, 2009

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

RANKL and RANK: From Mammalian Physiology to Cancer Treatment. Trends in Cell Biology 28(3): 213-223, 2017

RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends in Endocrinology and Metabolism: Tem 22(5): 188-194, 2011

Topical Treatment with Xiaozheng Zhitong Paste (XZP) Alleviates Bone Destruction and Bone Cancer Pain in a Rat Model of Prostate Cancer-Induced Bone Pain by Modulating the RANKL/RANK/OPG Signaling. Evidence-Based Complementary and Alternative Medicine 2015: 215892-215892, 2015

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biology & Therapy 9(7): 539-550, 2010